Press Releases

Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic
Press Release

September 29, 2021

Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic

Research to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome, debilitating disorders with no FDA-approved treatments

Read More
Press Release

April 20, 2021

Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officer

Life sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial

Read More
Press Release

October 28, 2020

Castle Creek Biosciences Announces First Patient Dosed in DeFi-RDEB Phase 3 Clinical Trial of D-Fi Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Company manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area

Read More
Press Release

October 15, 2020

Castle Creek Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of FCX-013 Gene Therapy for Treatment of Moderate to Severe Localized Scleroderma

Study targets a chronic autoimmune skin disorder affecting approximately 50,000 patients in the U.S.

Read More
Press Release

March 25, 2020

Castle Creek Biosciences Announces $75 Million Investment to Advance Development of Multiple Gene Therapy Candidates for Rare Diseases

Leveraging proprietary technology and manufacturing platform to develop transformative gene therapies for multiple rare diseases with high unmet needs

Read More

Join Our Mailing List

Keep up-to-date on our news & events

Subscribe